FDA Approves Solzaritinib for EGFR Exon 20 Lung Cancer With 42% Response Rate

What Is Solzaritinib and Why Is EGFR Exon 20 Lung Cancer Hard to Treat?

EGFR exon 20 insertion mutations account for approximately 10-12% of all EGFR-mutated non-small cell lung cancers (NSCLC), affecting thousands of new patients annually in the United States. Unlike the more common exon 19 deletions and L858R point mutations that respond well to first- through third-generation EGFR tyrosine kinase inhibitors, exon 20 insertions create a unique protein conformation that renders standard EGFR drugs ineffective. Historically, these patients had limited options beyond platinum-based chemotherapy, with response rates of only 15-25%.

Solzaritinib (formerly CLN-081) is an oral tyrosine kinase inhibitor designed with a novel binding mode that specifically accommodates the structural changes caused by exon 20 insertion mutations while maintaining selectivity against wild-type EGFR. This selectivity is critical because it reduces the skin rash, diarrhea, and other toxicities associated with less selective EGFR inhibitors. The drug was developed by Cullinan Oncology in partnership with Taiho Pharmaceutical and received Breakthrough Therapy designation from the FDA in 2023 based on promising early clinical data.

What Were the Results of the Pivotal Registrational Trial?

The registrational study enrolled patients with EGFR exon 20 insertion-mutated NSCLC who had progressed after at least one prior line of therapy including platinum-based chemotherapy. Patients received solzaritinib 100 mg orally twice daily. The confirmed objective response rate (ORR) assessed by blinded independent central review was approximately 42%, including both complete and partial responses. The disease control rate reached approximately 89%, and the median duration of response exceeded 12 months.

Median progression-free survival (PFS) was approximately 11 months, a substantial improvement over the 4-5 months typically seen with chemotherapy in this population. Overall survival data showed promising trends. The safety profile was manageable: the most common adverse events were diarrhea (reported in roughly half of patients, with severe cases in a small minority), rash (approximately 30%), and nausea (approximately 20%). Dose reductions were required in a minority of patients, and treatment discontinuation due to adverse events was low. Results were presented at a major oncology conference and submitted to a leading peer-reviewed journal.